Cellev8 and Zyppah Team Up to Give Snoring a Rest
Cellev8 and Zyppah have announced a collaborative sales agreement targeting 90 million Americans affected by snoring. The partnership combines Cellev8's SOD-based inflammation and recovery gummies with Zyppah's anti-snoring devices. The global anti-snoring devices market, valued at $1.52 billion in 2022, is projected to reach $2.65 billion by 2030. Undiagnosed sleep apnea costs the U.S. economy approximately $149.6 billion annually. The joint offering will be available starting November 1, 2024, through both companies' websites with specific discount codes and subscription models.
Cellev8 e Zyppah hanno annunciato un accordo di vendita collaborativo mirato a 90 milioni di americani colpiti dal russare. La partnership combina le gomme anti-infiammatorie e di recupero a base di SOD di Cellev8 con i dispositivi anti-russamento di Zyppah. Il mercato globale dei dispositivi anti-russamento, valutato a 1,52 miliardi di dollari nel 2022, è proiettato a raggiungere 2,65 miliardi di dollari entro il 2030. L'apnea notturna non diagnosticata costa all'economia statunitense circa 149,6 miliardi di dollari all'anno. L'offerta congiunta sarà disponibile a partire dal 1° novembre 2024, tramite i siti web di entrambe le aziende con codici sconto specifici e modelli di abbonamento.
Cellev8 y Zyppah han anunciado un acuerdo de ventas colaborativo dirigido a 90 millones de estadounidenses afectados por el ronquido. La asociación combina las gomitas de recuperación e inflamación a base de SOD de Cellev8 con los dispositivos anti-ronquidos de Zyppah. El mercado global de dispositivos anti-ronquidos, valorado en 1.52 mil millones de dólares en 2022, se proyecta que alcanzará los 2.65 mil millones de dólares para 2030. La apnea del sueño no diagnosticada cuesta a la economía de EE. UU. aproximadamente 149.6 mil millones de dólares anuales. La oferta conjunta estará disponible a partir del 1 de noviembre de 2024, a través de los sitios web de ambas compañías con códigos de descuento específicos y modelos de suscripción.
Cellev8와 Zyppah가 코골이로 인해 영향을 받는 9천만 미국인을 대상으로 협력 판매 계약을 체결했다고 발표했습니다. 이 파트너십은 Cellev8의 SOD 기반 염증 및 회복 젤리와 Zyppah의 코골이 방지 장치를 결합합니다. 2022년 15억 2천만 달러로 평가된 글로벌 코골이 방지 장치 시장은 2030년까지 26억 5천만 달러에 이를 것으로 예상됩니다. 진단되지 않은 수면 무호흡증은 미국 경제에 연간 약 1,496억 달러의 비용을 초래합니다. 공동 제공은 2024년 11월 1일부터 두 회사의 웹사이트에서 특정 할인 코드와 구독 모델을 통해 사용할 수 있습니다.
Cellev8 et Zyppah ont annoncé un accord de vente collaboratif visant 90 millions d'Américains touchés par le ronflement. Le partenariat combine les gommes à base de SOD de Cellev8 pour l'inflammation et la récupération avec les dispositifs anti-ronflement de Zyppah. Le marché mondial des dispositifs anti-ronflement, évalué à 1,52 milliard de dollars en 2022, devrait atteindre 2,65 milliards de dollars d'ici 2030. L'apnée du sommeil non diagnostiquée coûte à l'économie américaine environ 149,6 milliards de dollars par an. L'offre conjointe sera disponible à partir du 1er novembre 2024, via les sites Web des deux entreprises avec des codes de réduction spécifiques et des modèles d'abonnement.
Cellev8 und Zyppah haben eine gemeinsame Verkaufsvereinbarung angekündigt, die sich an 90 Millionen Amerikaner richtet, die von Schnarchen betroffen sind. Die Partnerschaft verbindet die SOD-basierten Entzündungs- und Erholungs-Gummis von Cellev8 mit den Anti-Schnarch-Geräten von Zyppah. Der globale Markt für Anti-Schnarch-Geräte, der 2022 mit 1,52 Milliarden Dollar bewertet wurde, wird bis 2030 voraussichtlich 2,65 Milliarden Dollar erreichen. Nicht diagnostizierte Schlafapnoe kostet die US-Wirtschaft jährlich etwa 149,6 Milliarden Dollar. Das gemeinsame Angebot wird ab dem 1. November 2024 über die Websites beider Unternehmen mit speziellen Rabattcodes und Abonnementmodellen verfügbar sein.
- Partnership targets a large market of 90 million snoring Americans
- Access to established customer base of 500,000+ Zyppah users
- Potential for tens of millions in sales according to CEO
- Entry into $1.52B global anti-snoring market with 37.6% North American share
- None.
Cellev8 and Zyppah Announce Collaborative Sales Agreement Targeting 90 Million Snoring Americans.
WELLINGTON, FL / ACCESSWIRE / October 29, 2024 / Cellev8 and Zyppah Announce Collaborative Sales Agreement Targeting 90 Million Snoring Americans.
Cellev8, a leading provider of Superoxide Dismutase (SOD) gummies, and Zyppah, the innovator of patented anti-snoring devices, have joined forces in a groundbreaking collaborative sales agreement. This partnership aims to address the needs of the estimated 90 million Americans affected by snoring, offering a comprehensive solution for better sleep and enhanced recovery.
The Economic Impact of Snoring and Sleep Apnea
Recent studies have highlighted the staggering financial burden of snoring and sleep apnea:
Undiagnosed sleep apnea costs the U.S. economy approximately
$149.6 billion annually.Healthcare costs related to sleep apnea amount to
$30 billion per year in increased utilization and medication expenses.Individuals with sleep apnea spend an average of
$2,105 annually on related medical expenses.The global anti-snoring devices and snoring surgery market was valued at
$1.52 billion in 2022, with North America holding a37.6% market share.This market is projected to reach
$2.65 billion globally by 2030.
Snoring and Inflammation
The impact of snoring-related inflammation can lead to various health issues:
Increased risk of cardiovascular diseases, diabetes, and neurodegenerative conditions.
Higher levels of C-reactive protein (CRP), a marker of inflammation, in severe snorers.
Potential damage to the endothelial cells lining blood vessels, contributing to cardiovascular problems.
Cellev8's Product and Its Potential Benefits
Cellev8's Inflammation and Recovery Gummies, containing clinically proven SOD2 and other mega antioxidants, could potentially help the snoring population by:
Reducing oxidative stress: SOD is a potent antioxidant that neutralizes superoxide radicals, which are elevated in chronic inflammatory conditions.
Combating inflammation: Our clinically proven SOD2 has shown anti-inflammatory properties in various studies, helping to mitigate inflammatory effects.
Supporting overall health: The combination of clinically proven SOD2 and other antioxidants in Cellev8's product may additionally help protect against the cellular damage associated with chronic inflammation.
Michael Ferraro, CEO of Cellev8 Nutrition, stated: "By addressing the underlying inflammation associated with snoring, we believe Cellev8's product could help reduce the risk of related health complications and improve overall well-being for the millions affected by snoring. We are proud to be working with such a successful and innovative company like Zyppah. It seems like everyone snores and Zyppah's solutions have helped so many people put that to bed-no pun intended-over the years, from mom and dad all the way to famous people like Shaquille O'Neal. We are confident that adding SOD and the other powerful all-natural ingredients contained in the Cellev8 line of products will not only help people sleep better but also notice improvements like natural energy during the day, faster recovery from workouts and fatigue, and an overall feeling of being healthier every day. "Ferraro added: "We have seen the results in some of the top athletes in the world and we have seen amazing results from children to the elderly. We are excited to help the nearly 90 million people in the US alone rest, sleep, and recover better. We believe this relationship could generate tens of millions in sales but most importantly it addresses the serious health aspects of snorers and provides them an all-natural tasty gummy that can help. "Dr. Jonathan Greenburg, founder and CEO of Zyppah, commented: "This collaboration with Cellev8 aligns perfectly with our mission to give everyone great sleep every night of their lives. By combining our snoring solutions, which have already helped over 500,000 customers, with Cellev8's recovery gummies, we're offering a more comprehensive approach to sleep health and overall well-being. Cellev8's Inflammation and Recovery Gummies could be one of the best supplements ever created. They are crafted with Superoxide Dismutase (SOD) and combined with mega antioxidants to impact the very root of most evils in the body-inflammation. SOD is the most important enzymatic antioxidant that your body produces to protect your cells. Having such a product available in the form of a tasty gummy could change the supplemental wellness market forever. We are proud to be a sales partner of Cellev8 and look forward to helping change wellness for the future."
Availability
The joint offering will provide millions of potential people the opportunity to buy the Cellev8 product line along with Zyppah's benefits through its discount and subscription model. The offering could start as soon as November 1, 2024 at Zyppah.com. The products will also be available on Cellev8.com with specific codes for Zyppah-driven customers and their associated discounts. Ferraro added: "This is a true game changer, and we have already witnessed the results and now millions of others can too."
About Cellev8:
Cellev8 Nutrition and the Cellev8 line of products harness the powerful antioxidant SOD and combine it with other mega ingredients to create supplements that repair, rejuvenate, and restore the body from a cellular level providing positive results for people's health.
About Zyppah:
Zyppah is the creator of FDA-cleared, clinically proven anti-snoring devices. With a
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Contact Information
Michael Ferraro
CEO
mike@cellev8.com
561-578-0000
SOURCE: Cellev8 Nutrition Inc.
View the original press release on accesswire.com
FAQ
When will Cellev8 and Zyppah's joint product offering become available?
What is the market size for anti-snoring devices that Cellev8 (CELV) is targeting?
How many potential customers could Cellev8 (CELV) reach through this partnership?
